Effects of testosterone suppression in young men by the gonadotropin releasing hormone antagonist cetrorelix on plasma lipids, lipolytic enzymes, lipid transfer proteins, insulin, and leptin.

Büchter D, Behre HM, Kliesch S, Chirazi A, Nieschlag E, Assmann G, von Eckardstein A

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association1 Jan 1999Cited by 18 (Europe PMC)

PMID10612483DOI10.1055/s-0029-1232561PepBankPUB-10612483

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In men, cetrorelix in groups C + C and C + P did not lead to considerable or consistent changes in LCAT, PLTP, CETP, lipoprotein lipase or hepatic lipase activities versus baseline and group P + P.
In plain wordsIn men, neither cetrorelix regimen led to considerable or consistent changes in lipid enzyme and transfer protein activities compared with baseline and placebo.
Peptide
Cetrorelix
Outcome
Direction not reportedLipid enzyme and transfer protein activities by regimen
Study
n = 10
Comparator
Baseline and placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Compared to baseline and group P + P, treatment with cetrorelix in groups C + C and C + P did not lead to considerable or consistent changes in the plasma activities of lecithin:cholesterol acyltransferase (LCAT), phospholipid transfer protein (PLTP), cholesteryl ester transfer protein (CETP), lipop…
4 context sentences(design, population, supporting numbers)
Summary · context
We investigated in a pilot study the effect of testosterone suppression on lipoprotein metabolism, insulin, and leptin in 10 men who were treated either with cetrorelix, an antagonist of gonadotropin releasing hormone, or with placebo (P).
Summary · context
Group C + C (n = 4) was treated with 10 mg cetrorelix as daily subcutaneous injections for five days and with a subsequent injection of 60 mg cetrorelix depot.
Summary · context
Group C + P (n = 3) received 10 mg cetrorelix as daily intramuscular injections for five days and a subsequent injection of placebo depot.
Summary · context
Group P + P (n = 3) received placebo both as daily and depot injections.
Report a problemFND-1061248304
02HumanNon-randomized trialEfficacy outcome
In men, cetrorelix increased serum apo A-I, HDL subclass LpA-I, insulin and leptin relative to baseline.
In plain wordsIn men, cetrorelix increased apo A-I, LpA-I, insulin and leptin compared with baseline.
Peptide
Cetrorelix
Outcome
IncreaseApo A-I, LpA-I, insulin and leptin
Study
n = 7
Comparator
Baseline
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
10 mg daily for five days, followed by 60 mg cetrorelix depot or placebo depotAs given in this study (human).
Source sentences
Summary
Compared to baseline, treatment with cetrorelix increased serum levels of apolipoprotein (apo) A-I, HDL subclass LpA-I, insulin, and leptin.
4 context sentences(design, population, supporting numbers)
Summary · context
We investigated in a pilot study the effect of testosterone suppression on lipoprotein metabolism, insulin, and leptin in 10 men who were treated either with cetrorelix, an antagonist of gonadotropin releasing hormone, or with placebo (P).
Summary · context
Group C + C (n = 4) was treated with 10 mg cetrorelix as daily subcutaneous injections for five days and with a subsequent injection of 60 mg cetrorelix depot.
Summary · context
Group C + P (n = 3) received 10 mg cetrorelix as daily intramuscular injections for five days and a subsequent injection of placebo depot.
Summary · context
Group P + P (n = 3) received placebo both as daily and depot injections.
Report a problemFND-1061248303
03HumanNon-randomized trialEfficacy outcome
In men, pooled cetrorelix regimens produced a small significant decrease in hepatic lipase activity.
In plain wordsIn men, pooled cetrorelix regimens slightly lowered hepatic lipase activity.
Peptide
Cetrorelix
Outcome
DecreasePooled hepatic lipase activity
Study
n = 7
Outcome group
Lipids · Metabolic and weight
Studied dose
10 mg daily for five days, followed by 60 mg cetrorelix depot or placebo depotAs given in this study (human).
Source sentences
Summary
Only the pooled data of groups C + C and C + P unraveled small but statistically significant decreases of HL and CETP activities in response to cetrorelix.
5 context sentences(design, population, supporting numbers)
Summary · context
Compared to baseline and group P + P, treatment with cetrorelix in groups C + C and C + P did not lead to considerable or consistent changes in the plasma activities of lecithin:cholesterol acyltransferase (LCAT), phospholipid transfer protein (PLTP), cholesteryl ester transfer protein (CETP), lipop…
Summary · context
We investigated in a pilot study the effect of testosterone suppression on lipoprotein metabolism, insulin, and leptin in 10 men who were treated either with cetrorelix, an antagonist of gonadotropin releasing hormone, or with placebo (P).
Summary · context
Group C + C (n = 4) was treated with 10 mg cetrorelix as daily subcutaneous injections for five days and with a subsequent injection of 60 mg cetrorelix depot.
Summary · context
Group C + P (n = 3) received 10 mg cetrorelix as daily intramuscular injections for five days and a subsequent injection of placebo depot.
Summary · context
Group P + P (n = 3) received placebo both as daily and depot injections.
Report a problemFND-1061248305
04HumanNon-randomized trialEfficacy outcome
In men, pooled cetrorelix regimens produced a small significant decrease in CETP activity.
In plain wordsIn men, pooled cetrorelix regimens slightly lowered CETP activity.
Peptide
Cetrorelix
Outcome
DecreasePooled CETP activity
Study
n = 7
Outcome group
Lipids · Metabolic and weight
Studied dose
10 mg daily for five days, followed by 60 mg cetrorelix depot or placebo depotAs given in this study (human).
Source sentences
Summary
Only the pooled data of groups C + C and C + P unraveled small but statistically significant decreases of HL and CETP activities in response to cetrorelix.
5 context sentences(design, population, supporting numbers)
Summary · context
Compared to baseline and group P + P, treatment with cetrorelix in groups C + C and C + P did not lead to considerable or consistent changes in the plasma activities of lecithin:cholesterol acyltransferase (LCAT), phospholipid transfer protein (PLTP), cholesteryl ester transfer protein (CETP), lipop…
Summary · context
We investigated in a pilot study the effect of testosterone suppression on lipoprotein metabolism, insulin, and leptin in 10 men who were treated either with cetrorelix, an antagonist of gonadotropin releasing hormone, or with placebo (P).
Summary · context
Group C + C (n = 4) was treated with 10 mg cetrorelix as daily subcutaneous injections for five days and with a subsequent injection of 60 mg cetrorelix depot.
Summary · context
Group C + P (n = 3) received 10 mg cetrorelix as daily intramuscular injections for five days and a subsequent injection of placebo depot.
Summary · context
Group P + P (n = 3) received placebo both as daily and depot injections.
Report a problemFND-1061248306
05HumanNon-randomized trialEfficacy outcome
In men, cetrorelix followed by cetrorelix depot reversibly suppressed testosterone to castrate levels for three weeks.
In plain wordsIn men, cetrorelix followed by cetrorelix depot lowered testosterone to castrate levels for three weeks, reversibly.
Peptide
Cetrorelix
Outcome
DecreaseTestosterone suppression with depot
Study
n = 4
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
10 mg daily for five days, then 60 mg depot · subcutaneous daily injectionsAs given in this study (human).
Measurements
Duration of testosterone suppression to castrate levels
3 weeks
Group C + C
Source sentences
Summary
Treatment with cetrorelix reversibly suppressed testosterone to castrate levels for three weeks in group C + C and for one week in group C + P.
4 context sentences(design, population, supporting numbers)
Summary · context
We investigated in a pilot study the effect of testosterone suppression on lipoprotein metabolism, insulin, and leptin in 10 men who were treated either with cetrorelix, an antagonist of gonadotropin releasing hormone, or with placebo (P).
Summary · context
Group C + C (n = 4) was treated with 10 mg cetrorelix as daily subcutaneous injections for five days and with a subsequent injection of 60 mg cetrorelix depot.
Summary · context
Group C + P (n = 3) received 10 mg cetrorelix as daily intramuscular injections for five days and a subsequent injection of placebo depot.
Summary · context
Group P + P (n = 3) received placebo both as daily and depot injections.
Report a problemFND-1061248301
06HumanNon-randomized trialEfficacy outcome
In men, cetrorelix followed by placebo depot reversibly suppressed testosterone to castrate levels for one week.
In plain wordsIn men, cetrorelix followed by placebo depot lowered testosterone to castrate levels for one week, reversibly.
Peptide
Cetrorelix
Outcome
DecreaseTestosterone suppression without active depot
Study
n = 3
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
10 mg daily for five days · intramuscular · five daysAs given in this study (human).
Measurements
Duration of testosterone suppression to castrate levels
1 weeks
Group C + P
Source sentences
Summary
Treatment with cetrorelix reversibly suppressed testosterone to castrate levels for three weeks in group C + C and for one week in group C + P.
4 context sentences(design, population, supporting numbers)
Summary · context
We investigated in a pilot study the effect of testosterone suppression on lipoprotein metabolism, insulin, and leptin in 10 men who were treated either with cetrorelix, an antagonist of gonadotropin releasing hormone, or with placebo (P).
Summary · context
Group C + C (n = 4) was treated with 10 mg cetrorelix as daily subcutaneous injections for five days and with a subsequent injection of 60 mg cetrorelix depot.
Summary · context
Group C + P (n = 3) received 10 mg cetrorelix as daily intramuscular injections for five days and a subsequent injection of placebo depot.
Summary · context
Group P + P (n = 3) received placebo both as daily and depot injections.
Report a problemFND-1061248302

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Effects of testosterone suppression in young men by the gonadotropin releasing hormone antagonist cetrorelix on plasma lipids, lipolytic enzymes, lipid transfer proteins, insulin, and leptin.

Summary

Results from this study6

Version history

Subjects

Publication types

MeSH terms